Results 141 to 150 of about 993 (163)
Early use of the novel antifungal rezafungin: a case series and literature review
Journal of Antimicrobial ChemotherapyAbstract Objectives Rezafungin is a novel echinocandin with a unique structural configuration enabling weekly IV dosing. We report on early use of rezafungin in our outpatient parenteral antibiotic therapy (OPAT) service, reviewing indications, treatment regimens, outcomes and adverse events in adult ...
Tihana Bicanic, Harriet Davidson
exaly +4 more sources
Expert Opinion on Drug Metabolism and ToxicologyRezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.Herein, we discuss the role of rezafungin in the treatment of candidemia and invasive candidiasis, with a specific focus on ...
Matteo Bassetti +2 more
exaly +7 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Rezafungin: A Novel Antifungal for the Treatment of Invasive Candidiasis
Future Microbiology, 2021Rezafungin is a novel echinocandin with exceptional stability and solubility and a uniquely long half-life allowing for front-loaded drug exposure with once-weekly dosing. Rezafungin has been shown comparable to other echinocandins, with activity against Candida spp. and Aspergillus spp.
George Thompson
exaly +3 more sources
Formulary Drug Review: Rezafungin
Hospital Pharmacy, 2023Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees.
Brittney Kessel, Danial E. Baker
openaire +2 more sources
Drugs, 2023
Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3-β-D-glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options.
openaire +2 more sources
Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3-β-D-glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options.
openaire +2 more sources
Clinical Microbiology and InfectionA post hoc analysis used pooled STRIVE/ReSTORE trial data to determine outcomes with rezafungin versus caspofungin by Candida species and antifungal susceptibility.
Taylor Sandison
exaly +2 more sources
Rezafungin: A Review in Invasive Candidiasis
DrugsRezafungin (Rezzayo®) is a next-generation echinocandin antifungal with improved pharmacokinetic properties over first-generation echinocandins that allows for once-weekly rather than once-daily intravenous administration. It has recently been approved for the treatment of adults with invasive candidiasis in the EU and UK, and is approved for adults ...
Simon Fung, Matt Shirley
openaire +2 more sources
Rezafungin (Rezzayo) for Invasive Candida Infections
The Medical Letter on Drugs and TherapeuticsThe FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.
openaire +2 more sources
Expert Opinion on Pharmacotherapy
Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant Candida species, notably C. glabrata and C. auris, along with limitations in available treatments, highlights the urgent need for novel, effective antifungal agents.This review ...
Divisha, Sharma, Jose A, Vazquez
openaire +2 more sources
Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant Candida species, notably C. glabrata and C. auris, along with limitations in available treatments, highlights the urgent need for novel, effective antifungal agents.This review ...
Divisha, Sharma, Jose A, Vazquez
openaire +2 more sources